Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Sep 24, 2010

Premium

Vermillion has appointed Jeffrey Salzman as corporate director of reimbursement. Salzman previously was director of health plans and payor markets at Ipsogen and he worked for nine years at Quest Diagnostics as an executive in health planning.

Salzman will be responsible for expanding reimbursement for the company's OVA1 test, which launched in March and is being marketed by Quest.

"My priority will be to leverage my years of experience within the payor community as well as interfacing with Quest Diagnostics to build upon the coverage momentum currently underway," Salzman said in a statement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.